Abstract

Chronic lung diseases are often fatal and challenging to treat due to the lungs’ defense system against foreign particles. Nanocarrier-based lung drug delivery is evolving, offering great potential towards targeted therapy and reduced side effects by the virtue of its biophysical properties. Here we discuss various carriers, including polymeric, liposomes, solid lipid nanoparticles, hybrid, dendrimer, and inorganic nanocarriers and their clinical implications. We also discuss the factors causing nanoparticle-related toxicity and strategies used to utilize nanoparticles as novel lung drug delivery carriers for chronic lung diseases.